Abstract: In one embodiment, a rotating electric machine includes a rotor and a stator. The rotor is a rotor which is rotatable around a center axis. The stator surrounds the rotor from one radial side. The stator includes a back yoke, a coil unit, and a plurality of partition units. The back yoke has an annular shape centered on the center axis. The coil unit is disposed on the other radial side of the back yoke. The plurality of partition units partition a winding range in which the coil unit is disposed in a circumferential direction. Each of the partition units includes a magnetic body portion made of a magnetic material. A circumferential dimension of the magnetic body portion is less than a circumferential dimension of the winding range. A radial dimension of the magnetic body portion is ½ or more of a radial dimension of the coil unit.

Abstract: A rotating electric machine of an embodiment includes a stator, a rotor, a housing, and a cover member. The stator includes a stator core and a coil. The stator core includes a core back portion. The core back portion has an annular shape centered on a center axis. The coil is attached to the stator core. The coil is located on the radially inside of the core back portion. The coil includes a coil straight portion and a pair of coil end portions. The coil straight portion extends in a straight line shape along the axial direction. The pair of coil end portions respectively protrude in the axial direction from both axial end surfaces of the stator core. The cover member includes a first cover portion. The first cover portion contacts one coil end portion so that the coil end portion is bent toward an inner peripheral surface of the housing and is brought into contact with the inner peripheral surface of the housing.

Abstract: A rotating electric machine of an embodiment includes a stator, a rotor, a housing, and a cover member. The stator includes a stator core and a coil. The stator core includes a core back portion. The core back portion has an annular shape centered on a center axis. The coil is attached to the stator core. The coil is located on the radially inside of the core back portion. The coil includes a coil straight portion and a pair of coil end portions. The coil straight portion extends in a straight line shape along an axial direction. The pair of coil end portions respectively protrude from both axial end surfaces of the stator core in the axial direction. The cover member is attached to the stator. The cover member contacts the coil end portion and presses against the inner peripheral surface of the housing.

Abstract: The present invention relates to novel fragments of apolipoprotein E (ApoE). These ApoE fragments have a variety of uses including as components of vaccine compositions, particularly vaccines for the prevention or treatment of neurological disorders such as Alzheimer's disease. The ApoE fragments may also be used in screening methods and methods of detection.

Abstract: Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by A?, wherein Ar1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Ar2 represents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; X1 represents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.

Abstract: An input protection circuit includes: a first transistor of a field-effect type coupled in series between an input terminal and an electronic circuit, the input terminal receiving an input voltage, the electronic circuit receiving an input voltage, the first transistor switching to an off-state in a case where the input voltage is higher than a positive power supply voltage of the electronic circuit; a second transistor of a field-effect type coupled in series between the first transistor and the electronic circuit, the second transistor switching to an off-state in a case where the input voltage is lower than the negative power supply voltage of the electronic circuit; and a voltage control circuit configured to maintain gate-source voltages of the first transistor and the second transistor as voltages within a power supply voltage range of the electronic circuit based on the input voltage.

Abstract: A copolymerized polyether polyamide resin for coating on or for impregnation to a woven or knitted fabric, wherein elongation and elastic modulus of the copolymerized polyether polyamide resin are not less than 1000% and not more than 15 MPa, respectively. The copolymerized polyether polyamide resin has a constitution wherein said copolymerized polyether polyamide resin is such that a soft segment comprising a polyether polyamide constituted from a polyether diamine compound and a dicarboxylic acid compound is bonded to a hard segment comprising a polyamide constituted from an aminocarboxylic acid compound and/or a lactam compound.

Abstract: An input protection circuit includes: a first transistor of a field-effect type coupled in series between an input terminal and an electronic circuit, the input terminal receiving an input voltage, the electronic circuit receiving an input voltage, the first transistor switching to an off-state in a case where the input voltage is higher than a positive power supply voltage of the electronic circuit; a second transistor of a field-effect type coupled in series between the first transistor and the electronic circuit, the second transistor switching to an off-state in a case where the input voltage is lower than the negative power supply voltage of the electronic circuit; and a voltage control circuit configured to maintain gate-source voltages of the first transistor and the second transistor as voltages within a power supply voltage range of the electronic circuit based on the input voltage.

Abstract: The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing A?40 and A?42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? such as Alzheimer's disease or Down's syndrome.

Abstract: The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

Abstract: A fabric for an airbag includes a synthetic fiber woven fabric in which at least one side thereof is coated with a synthetic resin. A range of 0.1 to 10 g/m2 of the synthetic resin is adhered to the synthetic fiber woven fabric having a cover factor of less than 2000 and a FR value of 55% or more. Air permeability of the fabric under a pressure difference of 100 kPa after adhesion is 0.01 to 1.00 L/cm2/min. The synthetic resin can be a polyamide-based resin having a soft segment comprising a polyol with a number average molecular weight of 100 to 5000.

Abstract: A woven fabric for an airbag includes a synthetic fiber woven fabric having a cover factor of 2000 to 2500 in which at least one side thereof is coated with a synthetic resin. Air permeability of the woven fabric under a pressure difference of 100 kPa is 0.01 to 1.00 L/cm2/min. A resin film is present at an upper part of a single yarn at a thickness of 2 ?m or less on a central cross section of a weaving yarn part. A resin film is present at an upper part of a single yarn at a thickness of 2 to 30 ?m on a cross section at a border between weaving yarn parts. The synthetic resin can be a polyamide-based resin that includes a polyether compound of a number average molecular weight of 100 to 5000 as a soft segment.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: An object of the present invention is to provide a woven fabric for an airbag which is of low cost, is excellent in accommodability, and has air permeability satisfying the human body initial constraining performance. The present invention provides a woven fabric for an airbag comprising a synthetic fiber woven fabric having a cover factor represented by the equation 1 of 2000 to 2500 in which at least one side thereof is coated with a synthetic resin, wherein air permeability of the woven fabric under a pressure difference of 100 kPa is 0.01 to 1.00 L/cm2/min, and a resin film is present at an upper part of a single yarn at a thickness of 2 ?m or less on a central cross section of a weaving yarn part, while a resin film is present at an upper part of a single yarn at a thickness of 2 to 30 ?m on a cross section at a border between weaving yarn parts.

Abstract: An object of the present invention is to provide a fabric for an airbag which is of low cost, is excellent in accommodability, and has air permeability satisfying the human body initial constraining performance. The present invention provides a fabric for an airbag comprising a synthetic fiber woven fabric in which at least one side thereof is coated with a synthetic resin, characterized in that a range of 0.1 to 10 g/m2 of a synthetic resin is adhered to the synthetic fiber woven fabric having a cover factor represented by the equation 1 of less than 2000 and FR represented by the equation 2 of 55% or more, and air permeability of the fabric under a pressure difference of 100 kPa after adhesion is 0.01 to 1.00 L/cm2/min.

Abstract: A compound represented by Formula (I) is provided: wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C?C— or (2) a double bond etc., which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group which may be substituted, or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.